Magnitude Biosciences has secured £1.3 million in funding to accelerate the development of its VivoScan platform, which aims to improve drug discovery processes for pharmaceutical and biotechnology companies.

UK · 2026-09-15

1. Step 1 · The triggerMagnitude Biosciences secures £1.3m in new funding from investors, strengthening its balance sheet and extending its R&D runway.
2. Step 2 · Knock-onThe company accelerates development of its VivoScan platform, increasing procurement of lab services, equipment, and specialist inputs from UK SMEs.
3. Step 3 · Reaches youPharma and biotech customers gain access to improved drug discovery tools, raising demand for supporting R&D services and partnerships across the UK SME ecosystem.

The trigger is reported by the source below. The steps that follow are Branch²’s traced reasoning — how the shock could reach a business like yours, not a prediction.

Source: Business Live

This is automated analysis for information only. It is not investment advice, not a recommendation, and not a solicitation to buy or sell any security. Branch² is not authorised or regulated. Do your own research.